Study of iruplinalkib after lorlatinib for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is for people with advanced lung cancer whose tumors have an ALK gene change and who have already taken a medicine called lorlatinib. It tests a new drug, iruplinalkib, to see how well it works for those who stopped responding to or couldn't tolerate lorlatinib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced lung adenocarcinoma (a type of lung cancer).
- Your cancer must have an ALK gene change confirmed by a special lab test.
- You must have taken lorlatinib before and had your cancer get worse while on it, or you had side effects that stopped you from taking it.
- You must have started taking iruplinalkib in a real-world setting (not as part of another study).
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This real-world study looks at how often lorlatinib causes side effects in the brain and nervous system in people with advanced ALK-positive non-small cell lung cancer. The goal is to better understand these risks so doctors can help patients manage them.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
This study tracks people with advanced ALK-positive lung cancer who are taking or will start Iruplinalkib. It checks how well Iruplinalkib works in the real world and monitors safety.
This real-world study looks at how effective Iruplinalkib is for people with ALK-positive non-small cell lung cancer. It is open to patients who have already taken this drug, and will simply collect data from your regular medical care.
This trial tests whether taking Iruplinalkib pills after lung cancer surgery can lower the risk of cancer returning in people with stage IA ALK-positive non-small cell lung cancer that has high-risk features.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.